SBIR Phase II: Nano-scale Engineering via Grid-scale Computing: Designing, Optimizing and Manufacturing Cancer Therapeutics

这个小企业创新研究（SBIR）第二阶段项目将推进用于治疗神经胶质瘤的新药化合物的开发，这些化合物是通过电网供电，计算机辅助设计（CAD）软件和DNA纳米制造技术的创新组合设计和构建的。这些化合物是自组装的DNA纳米结构，用分子亚组分功能化，用于靶向和破坏恶性神经胶质瘤（脑）肿瘤。胶质瘤的预后很差，因为完全手术切除是不可能的，化疗（选择性差）会导致附带的脑损伤，因此需要以高特异性靶向和破坏胶质瘤细胞的治疗。这项研究的更广泛影响是通过创造革命性的新纳米药物改善疾病预后的社会效益。 该公司在该项目下的努力最初集中在创造一种有效的神经胶质瘤治疗方法上，但该公司的Escheremblix平台有潜力用于创造各种适应症的化合物。 在分子水平上“即插即用”的能力，使
通过PNL的计算和纳米制造技术，为精心设计和开发全新类型的药物材料打开了大门，这些药物材料可以解决大量不同的药物和
生物技术细分市场的适应症。

This Small Business Innovation Research (SBIR) Phase II project will advance the development of new drug compounds for the treatment of glioma, which have been designed and constructed with an innovative combination of grid-powered, computer-aided design (CAD) software and DNA nano-fabrication technology. The compounds are self-assembling DNA nanostructures functionalized with molecular subcomponents for targeting and destroying malignant glioma (brain) tumors. Prognosis for glioma is poor because complete surgical resection is impossible and chemotherapy (being poorly selective) leads to collateral brain damage, hence treatments are needed that target and destroy glioma cells with high specificity.The broader impacts of this research are the societal benefits associated with improved disease outcomes through the creation of revolutionary new nano-pharmaceuticals. The Company's efforts under this project are focused initially on creating an effective treatment for glioma, but the Company's Essemblix platform has the potential to be used to create compounds for a wide variety of 
indications. The ability to "plug and play" at the molecular level, made possible 
by PNL's computational and nano-fabrication technology, opens the door to the deliberate design and development of entirely new types of pharmaceutical materials that could address indications across a vast and diverse number of pharmaceutical and 
biotechnology market segments.